Financial Performance - The company's revenue for Q3 2022 reached ¥393,564,157.53, representing a 24.44% increase compared to the same period last year[7] - Net profit attributable to shareholders for Q3 2022 was ¥141,179,233.48, up 36.92% year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥136,195,203.60, reflecting a 32.95% increase compared to the previous year[7] - Total operating revenue for the third quarter of 2022 reached ¥1,067,558,819.36, an increase of 29.6% compared to ¥824,285,729.11 in the same period last year[38] - Net profit for the third quarter was ¥326,872,227.74, representing a 38.7% increase from ¥235,751,341.34 in the previous year[38] - The company reported a total comprehensive income of ¥321,964,378.52 for the quarter, up from ¥226,030,073.40 year-on-year[41] Assets and Equity - The total assets at the end of the reporting period amounted to ¥3,421,456,305.14, a significant increase of 79.96% from the end of the previous year[7] - Shareholders' equity attributable to the parent company reached ¥2,938,496,479.59, marking an increase of 111.14% year-on-year[7] - As of September 30, 2022, the total assets of Shenzhen Meihua Chuangyi Medical Technology Co., Ltd. amounted to approximately CNY 3.42 billion, a significant increase from CNY 1.90 billion at the beginning of the year, reflecting a growth of about 80%[31] - The total equity increased significantly to ¥2,938,496,479.59 from ¥1,391,743,044.90, showcasing strong growth in shareholder value[34] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥200,167,831.56, showing a 24.89% increase compared to the previous year[7] - Total cash inflow from operating activities reached CNY 1,156,899,010.52, up from CNY 811,576,073.48, reflecting a growth of 42.5%[45] - Cash outflow from operating activities totaled CNY 956,731,178.96, compared to CNY 651,306,751.91, marking an increase of 46.8%[45] - The ending balance of cash and cash equivalents increased to CNY 1,762,287,172.26, compared to CNY 309,323,643.49 at the end of the previous period[48] Expenses and Costs - Total operating costs amounted to ¥697,531,574.59, up 26.0% from ¥553,399,829.21 year-on-year[38] - Research and development expenses grew by 34.23% to approximately CNY 59.63 million, reflecting increased investment in R&D[16] - The company reported a 70.34% increase in income tax expenses to approximately CNY 49.41 million due to higher taxable income[16] - The company paid CNY 219,652,523.24 in employee compensation, an increase from CNY 167,068,371.29, reflecting a rise of 31.4%[45] Investments and Financing - Cash inflow from financing activities was CNY 1,386,398,127.71, significantly higher than CNY 112,750,192.85 in the previous period[48] - The net cash flow from financing activities was CNY 1,243,425,261.37, a turnaround from a net outflow of CNY -35,744,100.95[48] - Cash outflow for investment activities was CNY 409,254,174.72, down from CNY 1,712,157,211.02, indicating a reduction of 76.1%[45] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 38,094, with the largest shareholder holding 45.74%[20] Other Information - The company has not disclosed any significant new product developments or market expansion strategies in the current report[28] - There are no updates on mergers or acquisitions mentioned in the latest financial report[28] - The report does not provide specific future guidance or outlook for the upcoming quarters[28]
美好医疗(301363) - 2022 Q3 - 季度财报